WHAT IT MEANS FOR PATIENTSThe potential for more aggressive price cuts would enable wider access to GLP-1 drugs - the same ...

The list is a first step in negotiations and, given the timing, the details and final pricing will be left to President-elect ...

London’s Guy’s Hospital has become one of the first to prescribe weight-loss jabs. The central London hospital, part of the ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

The US plans to slash the price it pays for Novo Nordisk's Ozempic and Wegovy, the latest drugs to be targeted under legislation that's expected save the government more than $200 billion over a ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Investing.com -- Shares of Novo Nordisk (NYSE: NVO) fell 3.6% on Friday after the U.S. Department of Health and Human ...

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...

European stocks advanced for four consecutive weeks as miners rose on a report Rio Tinto Group and Glencore Plc have ...

Diana Collette went from size 16 to size 10 on weight loss drug Mounjaro. She coped well with the side effects too – nausea ...

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare ...